



## Alzinova to attend BIO-Europe 2024 - Europe's leading partnering conference for the life science industry

Alzinova AB (publ) (ticker: ALZ), a Swedish biopharma company specializing in the development of innovative therapies against Alzheimer's disease, today announces that it will participate at BIO-Europe 2024, which will take place November 4-6 in Stockholm, Sweden. BIO-Europe is Europe's largest partnering conference in life science and attracts leading actors from all over the world.

The conference offers a platform for companies like Alzinova to present their research and development to potential partners and investors. Focusing on Alzinova's innovative vaccine candidate, ALZ-101, which is aimed at neutralizing the toxic oligomeric forms of amyloid-beta – a key component in the development of Alzheimer's disease – the company looks forward to deepening contacts and exploring strategic collaborations.

*"We are very much looking forward to attending BIO-Europe 2024. This is a fantastic opportunity to showcase our latest research and development, and to discuss possible partnerships to advance our drug candidate ALZ-101 into new clinical trials,"* comments Tord Labuda, CEO Alzinova AB.

During the year, Alzinova has reported progress in the development of ALZ-101, where positive results from ongoing clinical studies strengthen the company's position in Alzheimer's research. At BIO-Europe, Alzinova will conduct meetings with potential partners in the pharmaceutical industry, research institutions and investors to advance the development of its therapies against Alzheimer's disease. BIO-Europe is known for its effective partnering meetings and opportunities to create long-term collaborations in the biotechnology and pharmaceutical sectors.

### **For more information, please contact:**

Tord Labuda, CEO

Tel: +46 (0)70 838 23 23

E-mail: [tord.labuda@alzinova.com](mailto:tord.labuda@alzinova.com)

### **About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally,



with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

**Attachments**

**Alzinova to attend BIO-Europe 2024 - Europe's leading partnering conference for the life science industry**